• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Interim data supports Vaxess shelf-stable flu vaccine patch

December 14, 2022 By Sean Whooley

Vaxess Technologies MIMIX vaccine patch
[Image from the Vaxess website]
Vaxess Technologies today announced positive interim results from a first-in-human trial of its influenza vaccine patch.

Cambridge, Massachusetts-based Vaxess evaluated VX-103, a monovalent seasonal influenza vaccine patch. The trial included 45 healthy patients and evaluated the H1N1 influenza antigen from Vaxess’ partner, GC Biopharma.

Delivery of the vaccine took place through the Vaxess Mimix patch.

Vaxess enrolled healthy adult volunteers between ages 18 and 39 years old. It evaluated the safety, reactogenicity, tolerability and immunogenicity profiles for two influenza vaccine dose levels. Those levels included H1 vaccine dose level 7.5 μg and standard H1 vaccine dose level 15 μg vs placebo. Subjects only wore their Mimix patches for five minutes.

According to a news release, patients reported the patches as well-tolerated with no serious or severe adverse events. Results at day 57 showed that Mimix-Flu significantly exceeded the 2007 FDA criteria for accelerated licensure of influenza vaccines. The 15ug and 7.5ug patches led to seroconversion rates of 85% and 77%, respectively. They each produced seroprotection rates of 92%.

“Only half of U.S. adults get a seasonal influenza vaccine,” said Michael Schrader, CEO and co-founder of Vaxess. “This exciting early data combining GC Biopharma Corp.’s safe and effective influenza vaccine with the MIMIX patch points to a future product that will overcome many of the barriers keeping this rate so low, including needlephobia, inconvenience, and side effects such as injection site pain. We look forward to working with GC Biopharma Corp. to rapidly move this product through the clinic to positively impact patients’ lives.”

Vaxess plans to follow subjects out to 180 days to evaluate long-term safety for the patch. It also intends to evaluate the durability of immune response for each vaccine dose level. In a subset of samples, it may study the breadth of influenza A H1 antigen responses.

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: Vaxess Technologies

IN CASE YOU MISSED IT

  • BD files patent infringement lawsuit against Baxter over infusion pump tech
  • Tandem Diabetes Care subsidiary earns new FDA clearance for insulin infusion set
  • Glucotrack can proceed with long-term glucose monitor study in Australia
  • Dexcom promotes Jake Leach to president role
  • Roche invests $550M to make Indianapolis a CGM manufacturing hub

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS